Covidien Ltd. http://www.alacrastore.com/company-snapshot/Covidien_Ltd-4006279 Friday, July 25, 2008 11:25:13 PM 4006279 Covidien Ltd. en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/spcred/650672spcred/650672normThe latest Full Report from S&Pglobal5/28/2008 12:54:02 PM400Full Report650672United StatesHealth Care EquipmentUnited StatesGlobal IssuersCorporationsCapital GoodsFull ReportA diverse portfolio of medical devices and products; Stable positions within its health care segments; The large contribution of disposable products to its revenue base; Many of its businesses enjoy high barriers to entry; and The pace of technological change is not overly demanding for certain products with more commodity-like characteristics. Significantly lower market share in certain of its medical device businesses where it competes with more formidable players; Pricing pressures; and Modest operating margins relative to peers. The ratings on Bermuda-based Covidien Ltd., a global medical device and products company, reflect a strong business profile, evidenced by a diverse portfolio of medical products, stable positions within the company's health care segments, and the large contribution of disposable products toUSA35101010 351010 3510 35Covidien Ltd.412374USACOVFULLGLOBISSCORPCapitalCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/spcred/650673spcred/650673normThe latest Summary from S&Pglobal5/28/2008 12:54:02 PM175Summary650673United StatesHealth Care EquipmentUnited StatesGlobal IssuersCorporationsCapital GoodsSummaryThe ratings on Bermuda-based Covidien Ltd., a global medical device and products company, reflect a strong business profile, evidenced by a diverse portfolio of medical products, stable positions within the company's health care segments, and the large contribution of disposable products to its revenue base. These strengths are somewhat offset by the commodity-like nature of certain products and by competitive pressures. The company's scale ($8.9 billion in fiscal 2007 revenues excluding discontinued operations) and moderate use of debt leverage support a modest financial risk profile. Covidien Ltd. and Tyco Electronics were spun off from parent Tyco International Ltd. on June 29, 2007. Covidien International, a Luxembourg company that directly owns all of the operating subsidiaries of Covidien Ltd., is theUSA35101010 351010 3510 35Covidien Ltd.412374USACOVSUMMARYGLOBISSCORPCapitalCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/spcred/650094spcred/650094normThe latest Research Update from S&Pglobal5/23/2008 1:04:50 PM175Research Update650094United StatesHealth Care EquipmentUnited StatesGlobal IssuersCorporationsCapital GoodsResearch UpdateOn May 23, 2008, Standard&Poor's Ratings Services revised its outlook on Bermuda-based Covidien Ltd. to positive from stable. This action reflects progress on correcting operational problems, a disciplined financial strategy of debt reduction and modest-sized acquisitions, and the settlement of the vast majority of legacy shareholder lawsuits. Our 'A-' ratings on the company, including the corporate credit rating, were affirmed. The ratings on Covidien, a global medical device and products company, reflect a strong business profile, evidenced by a diverse portfolio of medical products, stable positions within the company's health care segments, and the large contribution of disposable products to its revenue base. These strengths are somewhat offset by the commodity-like nature of certain products and by competitiveUSA35101010 351010 3510 35Covidien Ltd.412374USACOVRESUPDGLOBISSCORPCapitalCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/spcred/650093spcred/650093normThe latest News from S&Pglobal5/23/2008 1:04:00 PM100News650093United StatesHealth Care EquipmentUnited StatesGlobal IssuersCorporationsCapital GoodsNewsNEW YORK (Standard&Poor's) May 23, 2008--Standard&Poor's Ratings Services said today that it revised its outlook on Bermuda-based Covidien Ltd. to positive from stable. Our 'A-' ratings on the company, including the corporate credit rating, were affirmed. "This action reflects progress on correcting operational problems, a disciplined financial strategy of debt reduction and modest-sized acquisitions, and the settlement of the vast majority of legacy shareholder lawsuits," said Standard&Poor's credit analyst Cheryl Richer. The ratings on Covidien, a global medical device and products company, reflect a strong business profile, evidenced by a diverse portfolio of medical products, stable positions within the company's health care segments, and the large contribution of disposable products to its revenue base.USA35101010 351010 3510 35Covidien Ltd.412374USACOVNEWSGLOBISSCORPCapitalCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/storecontent/ccbn/T1849767ccbn/T1849767norm... - Covidien Ltd. - President, Pharmaceutical Products & Imaging Solutions Good morning, everyone. Thank you, Matt. I am going to move through these slides quickly. We have about ## minutes. It is a pleasure to be here. I hope to be able to handle any of your questions afterwards. Forward-looking statements, you are very familiar with this. This is my background. I am not going to dwell on that. But I have been hanging around this industry for a couple of decades now. I am going to present -- really focus on the pharmaceutical and imaging businesses of Covidien. As you can see, it represents a little over ##% of the overall net sales for ####. We are going to focus on these two businesses that are managed out of St. Louis Missouri.For the pharmaceutical products, this business is about a $### million business. In ####, about half of those sales came from our active pharmaceutical ingredient business and the other half came from our pharmaceutical -- ethical pharmaceutical business, which... 5/22/2008 10:07:00 AMCovidien Ltd.54.0000FinalCovidien Ltd. at Citigroup Healthcare Conference TranscriptCOV8:30am ETTranscriptT1849767Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/MW-0001-25260305newstex/MW-0001-25260305xml MONTREAL, QUEBEC, May ##, #### (Marketwire delivered by Newstex) -- Ambrilia Biopharma Inc. (TSX: AMB) today reported its financial results for the first quarter ended March ##, ####, and provided an update on its development programs....11000000110130001300000013007000040000000401600004016005040160480401602704016018070000000700100007001003070010020700100707001004070030000700300111016000110160010200000002002000020020085/14/2008 9:19:08 AM1800000018016000180180001802200019000000190020001900200719002018MarketwireMW-0001-25260305AMBRILIA BIOPHARMA INCCOVIDIEN LTD.AMBFFAMBUFCOVNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/CCN-0001-25260945newstex/CCN-0001-25260945xml MONTREAL, QUEBEC, May ##, #### (Marketwire delivered by Newstex) -- Ambrilia Biopharma Inc. (TSX:AMB) today reported its financial results for the first quarter ended March ##, ####, and provided an update on its development programs....11000000110130001300000013007000040000000401600004016005040160480401602704016018070000000700100007001003070010020700100707001004070030000700300111016000110160010200000002002000020020085/14/2008 9:19:07 AM1800000018016000180180001802200019000000190020001900200719002018Marketwire CanadaCCN-0001-25260945AMBRILIA BIOPHARMA INCCOVIDIEN LTD.MERCK & CO INCAMBFFAMBUFCOVMRKNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-25258387newstex/MW-0001-25258387xml MONTREAL, QUEBEC, May ##, #### (Marketwire delivered by Newstex) -- Ambrilia Biopharma Inc. (TSX: AMB) today reported positive ##-week Phase III ("Study ###") top-line results for its proprietary prolonged-release formulation of Octreotide...0400000004002000040020060401600004016048040160180401601307000000070010000700100407003000070030010701400007014012070140085/14/2008 8:16:30 AM1800000018008000180220001802000018015000MarketwireMW-0001-25258387AMBRILIA BIOPHARMA INCCOVIDIEN LTD.AMBFFAMBUFCOVNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/CCN-0001-25258928newstex/CCN-0001-25258928xml MONTREAL, QUEBEC, May ##, #### (Marketwire delivered by Newstex) -- Ambrilia Biopharma Inc. (TSX:AMB) today reported positive ##-week Phase III ("Study ###") top-line results for its proprietary prolonged-release formulation of Octreotide...0400000004002000040020060401600004016048040160180401601307000000070010000700100407003000070030010701400007014012070140085/14/2008 8:16:29 AM1800000018008000180220001802000018015000Marketwire CanadaCCN-0001-25258928AMBRILIA BIOPHARMA INCCOVIDIEN LTD.MERCK & CO INCAMBFFAMBUFCOVMRKNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B1819127ccbn/B1819127norm...COV reported #Q## net sales of $#.#b, GAAP diluted EPS from continuing operations was $#.##, and non-GAAP diluted EPS from continuing operations was $#.##. ... 5/6/2008 12:06:00 PMCovidien Ltd.54.0000EditedQ2 2008 Covidien Ltd. Earnings Conference Call SummaryCOV8:30am ETBriefB1819127Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1819127ccbn/T1819127norm...Great day, ladies and gentlemen, and welcome to the second quarter #### Covidien earnings conference call. My name is Katina, and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will conduct a question-and-answer session towards the end of this conference. (OPERATOR INSTRUCTIONS) As a reminder, this conference is being recorded for replay purposes. I would now like to turn the presentation over to our host for today's call, Mr. Cole Lannum, Vice President of Investor Relations. Please proceed. ... 5/6/2008 10:06:00 AMCovidien Ltd.54.0000FinalQ2 2008 Covidien Ltd. Earnings Conference Call TranscriptCOV8:30am ETTranscriptT1819127Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-25036014newstex/BW-0001-25036014xml HAMILTON, Bermuda, May #, #### (Business Wire) -- Covidien Ltd. (NYSE: COV; BSX: COV) today reported results for the second quarter of fiscal #### (January - March ####). Second-quarter net sales rose ##% to $#.# billion from $#.# billion...040000000401600004016018040160480401600104016047040160030400200004002006040090000400900204010000040100010400600004006005130000001300200013002005130100001301000507000000070140000701401207003000070030010200000002002000020020045/6/2008 9:37:28 AM1800000018004000180080001802000018012000180100001900000019001000Business WireBW-0001-25036014COVIDIEN LTD.COVNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1816742ccbn/T1816742norm... - Morgan Stanley - AnalystGlenn Reicin for Morgan Stanley, for those people on the webcast, with me is Rich Meelia, who is President and CEO of Covidien. I'm trying to think about the first question or a way we can open. And this year has been a strange year for you. When you first went on the road and talked about the split off from Tyco, the feedback from a lot of investors was confusing. That it wasn't clear what your goals were, how quickly you can move. And sort of looking back at the last six months, it was very clear what your intentions were. But you just, for whatever reason were not as explicit about them. Maybe give us a little bit of background here. What has happening behind the scenes? And what's been learned and accomplished over the last six months? ... 5/2/2008 11:05:00 AMCovidien Ltd.54.0000FinalCovidien Ltd. at Morgan Stanley 2008 Global Healthcare Unplugged Conference TranscriptCOV9:20am ETTranscriptT1816742Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-24200919newstex/BW-0001-24200919xml HAMILTON, Bermuda, Apr. #, #### (Business Wire) -- Covidien Ltd. (NYSE: COV, BSX: COV) today announced that one of its subsidiaries has acquired ##% of the outstanding shares of Tissue Science Laboratories and has declared the public...04000000040160000401601904002000040020061800000018013000Business Wire4/2/2008 8:16:30 AMBW-0001-24200919COVIDIEN LTD.COVNewsNewstexhttp://www.alacrastore.com/storecontent/fitch/380154_report_framefitch/380154_report_framepdfFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Covidien Ltd.858000733/27/2008 2:18:31 PM0103000001031700165Credit UpdateCOV380154_report_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/moodys/PR_149159_820547800moodys/PR_149159_820547800htmlMoody's assigns Prime-# short term rating to CovidienRating Action2/15/2008 12:31:18 AMCovidien International Finance S.A.820547800150.0000Newshtml820055586Covidien Ltd.Covidien International Finance S.A.; Covidien Ltd.PR_149159_820547800Credit & Investment ResearchMoody's Global Credit Researchhttp://www.alacrastore.com/storecontent/fitch/405660_pr_framefitch/405660_pr_framehtmlFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Covidien Ltd.858000732/14/2008 10:19:00 AM010300000103170085Press ReleaseCOV405660_pr_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/ccbn/T1735339ccbn/T1735339normQ# #### Covidien Ltd. Earnings Conference Call2/7/2008 4:06:00 PMCovidien Ltd.54.0000FinalQ1 2008 Covidien Ltd. Earnings Conference Call TranscriptCOV8:30am ETTranscriptT1735339Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/fitch/390153_pr_framefitch/390153_pr_framehtml81609655BSX80090628MRKUniversal Health Services, Inc.BMYThermo Fisher Scientific IncHCA Inc.Boston Scientific CorporationHealth Management Associates, Inc.Covidien Ltd.010300008008952680091740Beckman Coulter, Inc.800911138184138001031702WYE803613728036159280843884Allergan, Inc.80091591CAHTHCTenet Healthcare Corporation829531250103170080417179010000008036141975Cardinal Health, Inc.AGNBAXCommunity Health Systems, Inc.80089918Press ReleaseJNJ80092087ESRXEli Lilly & CompanyMcKesson CorporationAmerisourceBergen CorporationABTTMODaVita, Inc.80091166OMI80091013Johnson & JohnsonLLYAbbott LaboratoriesFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.Medco Health Solutions, IncLPNT12/5/2007 10:12:00 AMMerck & Company, Inc.WPIBaxter International, Inc.Bristol-Myers Squibb Company8008936901031703MCKHMASchering-Plough Corporation858000738184136580710410Lifepoint Hospitals, Inc.SGP01040000CYHWatson Pharmaceuticals, Inc.BEC80656236MHSDVA80089368Express Scripts, Inc.Owens & Minor, Inc.80090206UHS81683472COVWyethABC816834998009177380090087390153_pr_frameCredit & Investment ResearchFitchResearchhttp://www.alacrastore.com/storecontent/fitch/376123_pr_framefitch/376123_pr_framehtmlCovidien Ltd.8580007310/17/2007 6:26:00 PM010300000103170075Press ReleaseCOVFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.376123_pr_frameCredit & Investment ResearchFitchResearch